| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Rivaroxaban |
| Brand | Xarelto® |
| Indication | For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. |
| Assessment Process | |
| Rapid review commissioned | 17/08/2011 |
| Rapid review completed | 31/08/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 28/11/2011 |
| NCPE assessment completed | 24/02/2012 |
| NCPE assessment outcome | Cost effective at submitted price |
We consider that at the submitted price Rivaroxaban could be considered cost-effective for this indication.
